Transcript: The AUA and the SUO have come out with a number of, what I would call, white papers to help advise urologists as to what to do with patients that they would normally give BCG to during the BCG shortage. So for example, we no longer give BCG to patients with intermediate risk non-muscle invasive bladder cancer, which is patients with low grade papillary disease. We now predominantly use intravesical chemotherapy and we reserve BCG for patients with high grade T1 disease and CIS.